LFMD - LifeMD, Inc. Stock Price, Fair Value and News

7.78USD+0.06 (+0.78%)Market Closed

Market Summary

USD7.78+0.06

Market Closed

0.78%

LFMD Stock Price

View Fullscreen

LFMD RSI Chart

LFMD Valuation

Market Cap

326.5M

Price/Earnings (Trailing)

-14.06

Price/Sales (Trailing)

EV/EBITDA

-21.46

Price/Free Cashflow

20.04

LFMD Price/Sales (Trailing)

LFMD Profitability

Operating Margin

88.21%

EBT Margin

-10.64%

Return on Equity

-1.8K%

Return on Assets

-37.78%

Free Cashflow Yield

4.99%

LFMD Fundamentals

LFMD Revenue

Revenue (TTM)

163.6M

Rev. Growth (Yr)

33.26%

Rev. Growth (Qtr)

-1.6%

LFMD Earnings

Earnings (TTM)

-23.2M

Earnings Growth (Yr)

-96.61%

Earnings Growth (Qtr)

-52.58%

Breaking Down LFMD Revenue

52 Week Range

1.818.02

(Low)(High)

Last 7 days

-17.2%

Last 30 days

-22.4%

Last 90 days

8.6%

Trailing 12 Months

311.8%

How does LFMD drawdown profile look like?

LFMD Financial Health

Current Ratio

0.99

Debt/Equity

10.83

Debt/Cashflow

1.18

LFMD Investor Care

Shares Dilution (1Y)

30.48%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	163.6M	0	0	0
2023	123.1M	128.6M	135.8M	152.5M
2022	103.7M	111.9M	118.3M	119.0M
2021	51.2M	64.4M	78.4M	92.9M
2020	14.1M	20.5M	28.3M	37.3M
2019	9.4M	10.1M	10.7M	12.5M
2018	4.8M	6.1M	6.6M	8.3M
2017	3.8M	3.2M	3.9M	3.3M
2016	2.6M	3.5M	4.6M	5.2M
2015	810.0K	890.7K	1.0M	1.2M
2014	770.5K	644.2K	715.0K	714.2K
2013	725.5K	820.8K	763.4K	808.4K
2012	0	0	0	673.8K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of LifeMD, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 04, 2024	bhatia naveen	acquired	-	-	500	-
Mar 21, 2024	yecies eric harold	acquired	-	-	56,250	general counsel & cco
Mar 21, 2024	benathen marc david	acquired	-	-	75,000	chief financial officer
Mar 21, 2024	stan maria e.	acquired	-	-	20,000	principal accounting officer
Mar 21, 2024	alvarez nicholas p	acquired	-	-	75,000	chief acquisition officer
Mar 21, 2024	galluppi stefan	acquired	-	-	30,000	chief innovation officer
Mar 13, 2024	bhatia naveen	acquired	-	-	750	-
Nov 13, 2023	schreiber justin	acquired	-	-	50,000	chief executive officer
Nov 06, 2023	jindal piyush	acquired	94,500	2.52	37,500	-
Aug 31, 2023	velge bertrand	bought	235,800	3.93	60,000	-

Which funds bought or sold LFMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Laurion Capital Management LP	unchanged	-	568,417	2,936,350	0.03%
May 15, 2024	STATE STREET CORP	added	11.03	291,738	1,065,970	-%
May 15, 2024	Point72 Asset Management, L.P.	new	-	72,988	72,988	-%
May 15, 2024	CITADEL ADVISORS LLC	added	61.52	256,465	512,170	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	2,168	3,709,480	3,846,230	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-4,000	-	-%
May 15, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	new	-	329,834	329,834	0.01%
May 15, 2024	CANTOR FITZGERALD, L. P.	reduced	-61.92	-344,728	308,400	0.07%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	245	1,511,170	1,971,260	0.04%
May 15, 2024	683 Capital Management, LLC	sold off	-100	-249,164	-	-%

Are Funds Buying or Selling LFMD?

Are funds buying LFMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LFMD

No. of Funds

Unveiling LifeMD, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	divisadero street capital management, lp	9.8%	3,737,685	SC 13G/A
Oct 06, 2023	divisadero street capital management, lp	5.3%	1,916,592	SC 13G

Recent SEC filings of LifeMD, Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Apr 05, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading

Peers (Alternatives to LifeMD, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	479.9B	379.5B	11.20%	7.55%	31.24	1.26	12.96%	-25.81%
CI	96.4B	206.0B	-2.18%	28.90%	25.01	0.47	12.55%	-43.95%
HCA	84.6B	66.7B	2.85%	17.20%	15.46	1.27	9.59%	-4.59%
CVS	72.2B	360.9B	-16.66%	-17.14%	9.86	0.2	9.07%	78.49%
CNC	41.2B	155.5B	6.71%	14.75%	15.05	0.26	6.34%	84.42%
UHS	12.0B	14.7B	10.86%	33.14%	14.73	0.82	7.99%	19.23%
DVA	12.0B	12.3B	5.19%	38.43%	14.68	0.97	5.77%	58.74%
MID-CAP
CHE	8.6B	2.3B	-6.84%	5.15%	30.33	3.75	5.96%	18.29%
ACHC	6.2B	3.0B	-6.14%	-7.19%	-547.09	2.07	10.92%	-104.06%
AMEH	2.3B	1.5B	8.58%	22.04%	36.93	1.59	19.34%	40.15%
AMN	2.2B	3.5B	3.96%	-38.10%	15.61	0.64	-27.67%	-62.43%
SMALL-CAP
ADUS	1.8B	1.1B	13.47%	25.04%	27.49	1.66	11.45%	30.74%
BKD	1.4B	3.0B	11.90%	88.00%	-7.82	0.45	4.98%	4.88%
BEAT	55.6M	-	17.22%	-3.21%	-3.68	-	-	-1.05%
AMS	21.1M	21.6M	17.97%	25.63%	38.19	0.98	9.04%	-50.63%

LifeMD, Inc. News

Latest updates

LifeMD, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-1.6%	44,144,264	44,859,848	38,613,911	35,946,913	33,126,335	28,119,716	31,412,469	30,458,498	29,042,837	27,416,884	24,947,199	22,313,611	18,198,112	12,893,552	11,005,763	9,089,783	4,304,812	3,944,454	3,126,727	2,698,407	2,698,990
Cost Of Revenue	-14.1%	4,600,177	5,355,559	4,781,506	4,548,430	4,214,969	4,067,700	4,716,842	4,635,311	5,248,175	5,567,630	5,096,487	4,120,220	3,211,057	4,046,168	1,675,582	1,694,421	1,337,650	494,807	680,081	655,211	712,445
Gross Profit	0.1%	39,544,087	39,504,289	33,832,405	31,398,483	28,911,366	24,052,016	26,695,627	25,823,187	23,794,662	21,849,254	19,850,712	18,193,391	14,987,055	8,847,385	9,330,181	7,395,362	2,967,162	3,449,647	2,446,646	2,043,196	1,986,545
Operating Expenses	9.7%	45,715,332	41,675,825	38,401,786	36,294,029	31,764,176	34,422,957	33,761,328	38,727,312	36,901,677	35,513,931	32,442,016	34,320,154	26,905,392	41,175,454	29,862,688	10,613,734	4,707,667	3,969,016	3,420,352	2,876,360	2,549,914
S&GA Expenses	18.6%	24,173,880	20,389,121	19,776,797	19,567,903	16,717,645	17,440,781	17,200,859	21,817,966	21,909,825	21,192,126	20,293,935	22,392,179	18,640,731	17,384,395	10,528,833	8,394,331	2,745,882	3,135,526	2,073,016	2,215,913	1,692,178
EBITDA Margin	9.2%	-0.09	-0.10	-0.32	-0.34	-0.35	-0.36	-0.51	-0.53	-0.56	-0.63	-0.94	-1.26	-	-	-	-	-	-	-	-	-
Interest Expenses	3.6%	644,919	622,685	713,766	995,670	264,465	-	132,235	132,236	167,934	153,566	1,824,777	901,910	139,463	714,551	291,096	228,875	793,039	330,194	130,936	129,826	170,194
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-17,998,716	-14,416,081	-17,028,673	-11,872,886	-33,597,457	-20,823,603	-3,447,247	-2,533,544	-849,562	-1,104,642	-962,990	-733,563
EBT Margin	6.7%	-0.11	-0.11	-0.33	-0.35	-0.36	-0.38	-0.52	-0.55	-0.59	-0.66	-0.98	-1.29	-	-	-	-	-	-	-	-	-
Net Income	-52.6%	-6,768,355	-4,435,984	-6,122,435	-5,891,216	-3,442,473	-11,970,713	-7,281,673	-12,972,961	-13,274,949	-17,877,008	-14,353,375	-17,028,673	-11,872,886	-32,147,255	-20,622,370	-3,447,247	-2,533,544	-604,196	-943,804	-962,990	-733,563
Net Income Margin	-8.9%	-0.14	-0.13	-0.20	-0.22	-0.29	-0.38	-0.43	-0.52	-0.60	-0.66	-0.96	-1.27	-	-	-	-	-	-	-	-	-
Free Cashflow	-10.3%	5,026,567	5,604,298	1,045,953	4,613,761	-2,647,594	-1,956,795	-2,797,548	-10,189,145	-8,358,294	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	5.1%	61.00	58.00	41.00	35.00	34.00	26.00	33.00	38.00	26.00	50.00	16.00	24.00	19.00	13.00	5.00	3.00	2.00	3.00	3.00	2.00	3.00
Current Assets	4.2%	44.00	43.00	25.00	20.00	19.00	11.00	13.00	19.00	30.00	45.00	14.00	22.00	18.00	12.00	5.00	2.00	2.00	3.00	2.00	1.00	2.00
Cash Equivalents	5.9%	35.00	33.00	15.00	12.00	12.00	4.00	6.00	12.00	25.00	41.00	9.00	17.00	13.00	9.00	1.00	0.00	0.00	1.00	1.00	0.00	0.00
Inventory	-14.0%	2.00	3.00	4.00	4.00	3.00	4.00	4.00	4.00	1.00	2.00	2.00	2.00	2.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
Net PPE	23.0%	1.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-
Goodwill	-	-	-	-	-	-	-	6.00	-	8.00	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	13.7%	60.00	53.00	52.00	46.00	41.00	33.00	30.00	31.00	34.00	24.00	31.00	28.00	16.00	14.00	13.00	8.00	6.00	5.00	3.00	4.00	2.00
Current Liabilities	28.4%	45.00	35.00	33.00	32.00	27.00	31.00	25.00	26.00	26.00	23.00	20.00	19.00	15.00	14.00	9.00	7.00	5.00	4.00	3.00	2.00	2.00
Long Term Debt	-21.5%	14.00	18.00	19.00	14.00	13.00	-	-	-	-	-	11.00	9.00	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	18.00	19.00	14.00	13.00	-	-	-	-	-	11.00	9.00	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-62.9%	1.00	4.00	-	-	-12.04	-11.87	-	2.00	12.00	22.00	-	-	-	-	-	-	-	-	-	-	0.00
Retained Earnings	-3.5%	-221	-214	-209	-202	-195	-190	-177	-169	-156	-141	-122	-108	-91.75	-80.15	-47.90	-23.71	-20.24	-16.59	-15.88	-14.94	-12.80
Additional Paid-In Capital	1.5%	221	218	197	187	183	179	177	173	169	165	105	101	92.00	78.00	41.00	19.00	16.00	16.00	15.00	13.00	13.00
Shares Outstanding	6.2%	41.00	38.00	35.00	32.00	32.00	31.00	31.00	31.00	31.00	31.00	27.00	26.00	-	-	-	-	-	-	-	-	-
Minority Interest	4.0%	2.00	2.00	2.00	1.00	-0.03	-0.48	-0.80	-1.03	-1.04	-1.03	-1.10	-1.00	-0.77	-2.18	-0.67	-0.47	-0.32	-0.14	-0.10	0.00	-0.18
Float	-	-	-	-	112	-	-	-	50.00	-	-	-	236	-	-	-	83.00	-	-	-	4.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-9.0%	5,202	5,714	1,076	4,644	-2,613	-1,969	-2,776	-10,098	-8,091	-5,825	-7,419	-10,733	-9,106	-6,536	-4,498	-1,758	661	159	-547	94.00	546
Share Based Compensation	-30.2%	2,544	3,646	3,318	2,862	2,664	1,885	3,336	4,041	4,473	4,088	3,111	2,547	2,326	1,757	16,364	439	96.00	207	167	191	155
Cashflow From Investing	1.2%	-2,190	-2,216	-2,403	-2,301	-1,811	-1,771	-2,241	-2,514	-7,378	-1,578	-853	-921	-48.86	-67.55	-53.42	-208	-468	400	-	-	-500
Cashflow From Financing	-107.3%	-1,047	14,361	4,709	-1,961	11,991	1,862	-862	-753	-774	39,285	305	15,663	13,383	14,866	5,132	1,946	-941	-233	1,063	-70.87	16.00
Dividend Payments	-100.0%	-	777	777	777	777	777	777	777	777	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LFMD Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues
Total revenues, net	$ 44,144,264	$ 33,126,335
Cost of revenues
Total cost of revenues	4,600,177	4,214,969
Gross profit	39,544,087	28,911,366
Expenses
Selling and marketing expenses	24,173,880	16,717,645
General and administrative expenses	15,305,732	10,602,763
Other operating expenses	2,300,447	1,704,765
Development costs	2,087,232	1,183,599
Customer service expenses	1,848,041	1,555,404
Total expenses	45,715,332	31,764,176
Operating loss	(6,171,245)	(2,852,810)
Interest expense, net	(477,678)	(264,465)
Loss on debt extinguishment		(325,198)
Net loss	(6,648,923)	(3,442,473)
Net income attributable to non-controlling interest	119,432	565,983
Net loss attributable to LifeMD, Inc.	(6,768,355)	(4,008,456)
Preferred stock dividends	(776,563)	(776,563)
Net loss attributable to LifeMD, Inc. common stockholders	$ (7,544,918)	$ (4,785,019)
Basic loss per share attributable to LifeMD, Inc. common stockholders	$ (0.19)	$ (0.15)
Diluted loss per share attributable to LifeMD, Inc. common stockholders	$ (0.19)	$ (0.15)
Weighted average number of common shares outstanding:
Basic	39,242,237	31,680,776
Diluted	39,242,237	31,680,776
Telehealth Revenue [Member]
Revenues
Total revenues, net	$ 30,841,402	$ 20,202,803
Cost of revenues
Total cost of revenues	4,194,595	3,920,182
WorkSimpli Revenue [Member]
Revenues
Total revenues, net	13,302,862	12,923,532
Cost of revenues
Total cost of revenues	$ 405,582	$ 294,787

LFMD Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash	$ 35,110,929	$ 33,146,725
Accounts receivable, net	5,336,491	5,277,250
Product deposit	288,938	485,850
Inventory, net	2,373,640	2,759,932
Other current assets	1,298,737	934,510
Total Current Assets	44,408,735	42,604,267
Non-current Assets
Equipment, net	585,980	476,303
Right of use assets	1,674,014	594,897
Capitalized software, net	12,023,248	11,795,979
Intangible assets, net	2,763,297	3,009,263
Total Non-current Assets	17,046,539	15,876,442
Total Assets	61,455,274	58,480,709
Current Liabilities
Accounts payable	12,395,032	11,084,855
Accrued expenses	14,555,480	13,937,494
Notes payable, net	115,907	327,597
Current operating lease liabilities	447,559	603,180
Current portion of long-term debt	3,958,333
Deferred revenue	13,202,757	8,828,598
Total Current Liabilities	44,675,068	34,781,724
Long-term Liabilities
Long-term debt, net	14,069,838	17,927,727
Noncurrent operating lease liabilities	1,311,452	73,849
Contingent consideration	100,000	131,250
Total Liabilities	60,156,358	52,914,550
Commitments and contingencies (Note 10)
Mezzanine Equity
Preferred Stock, $0.0001 par value; 5,000,000 shares authorized Series B Convertible Preferred Stock, $0.0001 par value; 5,000 shares authorized, zero shares issued and outstanding, liquidation value, $0 per share as of March 31, 2024 and December 31, 2023
Stockholders’ Equity (Deficit)
Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding, liquidation value approximately, $25.55 per share as of March 31, 2024 and December 31, 2023	140	140
Common Stock, $0.01 par value; 100,000,000 shares authorized, 40,731,676 and 38,358,641 shares issued, 40,628,636 and 38,255,601 outstanding as of March 31, 2024 and December 31, 2023, respectively	407,317	383,586
Additional paid-in capital	220,721,095	217,550,583
Accumulated deficit	(221,810,154)	(214,265,236)
Treasury stock, 103,040, at cost, as of March 31, 2024 and December 31, 2023	(163,701)	(163,701)
Total LifeMD, Inc. Stockholders’ (Deficit) Equity	(845,303)	3,505,372
Non-controlling interest	2,144,219	2,060,787
Total Stockholders’ Equity	1,298,916	5,566,159
Total Liabilities, Mezzanine Equity and Stockholders’ Equity (Deficit)	$ 61,455,274	$ 58,480,709

About LifeMD, Inc.

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including urgent and primary care, men's and women's health, and dermatology, chronic care management, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and food and drug administration approved medical device for male and female hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and NavaMD, a female-oriented and tele-dermatology brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. The company sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.

CEO	Mr. Justin Schreiber
WEBSITE	https://lifemd.com
INDUSTRY	Healthcare Plans
EMPLOYEES	199

LifeMD, Inc. Frequently Asked Questions

What is the ticker symbol for LifeMD, Inc.? What does LFMD stand for in stocks?

LFMD is the stock ticker symbol of LifeMD, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of LifeMD, Inc. (LFMD)?

As of Thu May 16 2024, market cap of LifeMD, Inc. is 326.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LFMD stock?

You can check LFMD's fair value in chart for subscribers.

What is the fair value of LFMD stock?

You can check LFMD's fair value in chart for subscribers. The fair value of LifeMD, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of LifeMD, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LFMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is LifeMD, Inc. a good stock to buy?

The fair value guage provides a quick view whether LFMD is over valued or under valued. Whether LifeMD, Inc. is cheap or expensive depends on the assumptions which impact LifeMD, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LFMD.

What is LifeMD, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, LFMD's PE ratio (Price to Earnings) is -14.06 and Price to Sales (PS) ratio is 2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LFMD PE ratio will change depending on the future growth rate expectations of investors.